![](images/graphics/blank.gif)
Bronchodilator treatment
-
Chronic obstructive pulmonary disease (COPD) is a common disease. There have been no studies evaluating patient characteristics, management and treatment status and short-term effectiveness of the short-acting bronchodilator combination of salbutamol/ipratropium in patients being managed by a respiratory facilities in Vietnam. This is the reason for this study.
7p
vigeorge
06-12-2023
3
2
Download
-
The objective of this study was to evaluate the comparative efficacy of indacaterol 75 μg once daily (OD), tiotropium 18 μg OD, salmeterol 50 μg twice daily (BID), formoterol 12 μg BID, and placebo for the treatment of chronic obstructive pulmonary disease (COPD) based on individual patient data (IPD) from randomized controlled trials (RCTs) from the indacaterol trial program and aggregate data (AD) identified from a systematic review of RCTs.
15p
vianthony2711
16-04-2021
5
1
Download
-
Although timely treatment of COPD exacerbations seems clinically important, nearly half of these exacerbations remain unreported and subsequently untreated. Recent studies have investigated incidence and impact of failure to seek medical treatment during exacerbations.
9p
vianthony2711
16-04-2021
14
2
Download
-
Umeclidinium (UMEC; long-acting muscarinic antagonist) plus vilanterol (VI; long-acting beta2 agonist [LABA]) and the LABA/inhaled corticosteroid fluticasone propionate/salmeterol (FP/SAL) are approved maintenance treatments for chronic obstructive pulmonary disease (COPD).
12p
vimontana2711
05-04-2021
8
2
Download
-
Indacaterol is a novel, once-daily (od), inhaled, long-acting ß2-agonist bronchodilator for maintenance treatment of airflow limitation in patients with COPD. The aim of this study was to evaluate the efficacy of indacaterol on dyspnea, using available randomized placebo-controlled trials.
8p
vimontana2711
05-04-2021
12
2
Download
-
Bronchodilators are a mainstay of treatment for patients with airflow obstruction. We hypothesized that patients with obesity and no objective documentation of airflow obstruction are inappropriately treated with bronchodilators.
6p
vimontana2711
05-04-2021
14
2
Download
-
Bronchodilator medications are central to the symptomatic management of chronic obstructive pulmonary disease (COPD). Metered-dose inhalers (MDIs) are the most commonly used devices to deliver treatment to patients with COPD and asthma, comprising approximately 70% of bronchodilator prescriptions.
10p
vimontana2711
05-04-2021
8
1
Download
-
Indacaterol is a long-acting beta-2 agonist for once-daily treatment of COPD. We evaluated the effects of indacaterol 150 μg on lung hyperinflation compared with placebo and open-label tiotropium 18 μg. We measured physical activity during treatment with indacaterol 150 μg and matched placebo.
8p
vimontana2711
05-04-2021
4
1
Download
-
Long-acting β2-adrenergic agonists (LABAs) are recommended in combination with inhaled corticosteroids (ICSs) for asthma management. Abediterol is a novel, selective, potent, once-daily LABA in development for treatment of asthma and chronic obstructive pulmonary disease.
10p
vimontana2711
05-04-2021
5
1
Download
-
In chronic obstructive pulmonary disease (COPD) patients, combination treatment with long-acting muscarinic antagonist (LAMA) and long-acting β2 agonist (LABA) increases forced expiratory volume in one second and reduces symptoms compared to monotherapy.
8p
vimichigan2711
26-03-2021
10
2
Download
-
Abediterol is a novel, once-daily long-acting β2-agonist in development for the treatment of chronic obstructive pulmonary disease (COPD) and asthma in combination with an anti-inflammatory agent. This Phase IIa, randomised, double-blind, crossover study investigated the bronchodilation, safety, tolerability and pharmacokinetics of abediterol in patients with moderate to severe COPD.
13p
vimaine2711
26-03-2021
10
2
Download
-
Inhaled bronchodilators including long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA) play a central role in the treatment of stable chronic obstructive pulmonary disease (COPD). However, it is still unclear whether LABA or LAMA should be used for the initial treatment.
11p
vimaine2711
26-03-2021
11
2
Download
-
In view of the effectiveness and relative safety of rapidacting 2-agonists, theophylline has a minimal role in the management of acute asthma. Its use is associated with severe and potentially fatal side effects, particularly in those on long-term therapy with slow-release theophylline, and its bronchodilator effect is less than that of 2-agonists.
78p
dacotaikhoan
26-04-2013
46
1
Download
-
Once COPD has been diagnosed, goals of treatment and management include relieving symptoms; preventing and treating disease progression, complications, and exacerbations; improving exercise tolerance, daily activity, and health status; monitoring nutritional needs; and reducing premature mortality (8).
6p
chiecxedien
03-01-2013
53
2
Download
-
Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học 'Respiratory Research cung cấp cho các bạn kiến thức về ngành y đề tài: " Tolerance to bronchodilation during treatment with long-acting beta-agonists, a randomised controlled trial...
7p
toshiba14
22-10-2011
49
3
Download
CHỦ ĐỀ BẠN MUỐN TÌM
![](images/graphics/blank.gif)